SB-267268

Antiangiogenic Agent; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Choroidal Neovascularization 09/01/2020 - "Preclinical candidates include SB-267268, AXT-107, JNJ-26076713, Cilengitide and Lebecetin, which exhibit a decrease in retinal permeability, angiogenesis and/or choroidal neovascularization (CNV). "
2.	Retinopathy of Prematurity (Retrolental Fibroplasia) 04/01/2006 - "To determine whether SB-267268, a nonpeptidic antagonist of the alpha(v)beta3 and alpha(v)beta5 integrins, attenuates angiogenesis in a murine model of retinopathy of prematurity (ROP) and alters the expression of vascular endothelial growth factor (VEGF) and its second receptor (VEGF-R2). " 04/01/2006 - "SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity."
3.	Pathologic Neovascularization 04/01/2006 - "SB-267268 reduced pathologic angiogenesis in ROP mice by approximately 50% and had no effect on developmental retinal angiogenesis in shams. "

1.	Retinaldehyde (Retinal)
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Integrins
4.	JNJ-26076713
5.	Cilengitide